Effect of Immersive Virtual Reality-based Cognitive Remediation in Patients With Mood - or Psychosis Spectrum Disorders

Effect of Immersive Virtual Reality-based Cognitive Remediation in Patients With Mood Disorders or Psychosis Spectrum Disorders: a Randomized, Controlled, Double-blinded Trial

The goal of this clinical trial is to investigate the effect of a four-weeks, intensive virtual reality (VR)-based cognitive remediation (training) programme involving simulated daily-life challenges on cognition and functional capacity in symptomatically stable patients with mood disorders (depression or bipolar disorder) or psychosis spectrum disorders (F20-F29; e.g. schizophrenia or schizotypal disorder).

The investigators hypothesize that VR-based cognitive remediation vs. a VR control treatment has a beneficial effect on cognition after four-weeks treatment completion (primary outcome assessement time) measured with a novel ecologically valid VR test of daily-life cognitive functions (The CAVIR test; primary outcome measure), a verbal learning and memory composite score based on a traditional neuropsychological test and a performance-based measure of daily functioning (secondary outcome measures). Finally, for exploratory purposes, the study will examine neuronal underpinnings of treatment effects, and effects on additional measures of cognition, functioning and self-ratings scales (tertiary outcomes).

Study Overview

• Status: Recruiting
• Conditions: Depression; Psychotic Disorders; Schizophrenia; Cognitive Impairment; Bipolar Disorder; Schizotypal Disorder
• Intervention / Treatment: Behavioral: Virtual reality Based Cognitive Remediation; Behavioral: Virtual reality control training

Detailed Description

The current study will include outpatients with a mood disorders (unipolar - or bipolar disorder) in full or partial remission at the time of inclusion (score ≤ 14 on the Hamilton Depression or a psychosis spectrum disorders (F20-F29) that have been assessed to be relatively symptom stable by their treating clinician upon referral to the study. To accommodate for an approximately 20% drop-out rate from baseline to treatment completion (the primary outcome assessement time point), the investigators will recruit up to 66 participants (33 participants per intervention arm) to obtain complete data for minimum 54 participants (27 participants per arm).

Recruitment will be carried out through the outpatient Copenhagen Affective Disorder Clinic, the outpatient, early intervention clinics for psychotic disorders (OPUS), other mental health centres in the Capital Region of Denmark, and through advertisements on relevant websites.

After inclusion, the baseline assessements are scheduled and completed over two days, one to five days apart. On day 1, the participant is assessed with the virtual cognition test (the CAVIR test) and a comprehensive neuropsychological test battery. Participants also complete questionnaires concerning subjective cognitive complaints, quality of life and general acceptance of virtual reality technology. Functional capacity is assessed using a clinician-rated interview and a performance-based assessment. For participants with mood disorders, mood symptoms are rated with the Hamilton Depression Rating Scale (HDRS-17) and Young Mania Rating Scale (YMRS). For participants with psychosis spectrum disorders, positive and negative symptoms are rated with the Scale for the Assessement of Positive symptoms (SAPS) and Brief Negative Symptom Scale (BNSS), respectively. Finally, sleep quantity and quality in the past 3 days is recorded. Later the same day an fMRI scan is carried out encompassing a spatial working memory N-back task, a word encoding paradigm in which participants must encode and subsequently recognize words of typical household items, a resting state, and a structural scan. On day 2, participants' daily life functional capacity is assessed with The Assessement of Motor and Process Skills (AMPS) by an AMPS-certified occupational therapist in a standardized test kitchen.

The virtual reality cognition test, neuropsychological assessments, questionnaires, clinical symptom ratings, assessements of functional capacity (including AMPS) and fMRI scan are repeated within 2 weeks of treatment completion (primary outcome assessement time). All assessments except for the fMRI scan are repeated again 3 months after treatment completion to assess durability.

Participants are randomized upon full completion of the baseline assessement with allocation being carried out using the automated randomization module in the online Research Electronic Data Capture (REDcap) system based on an uploaded blocked randomization list stratified by age (< or ≥ 35 years) and diagnosis (mood disorders v. psychosis spectrum disorder)

• Study Type: Interventional
• Enrollment (Estimated): 66
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Andreas Elleby Jespersen, PhD-student; Phone Number: +4528587815; Email: andreas.elleby.jespersen@regionh.dk
• Study Contact Backup: Name: Kamilla Woznica Miskowiak, DMSc, DPhil; Phone Number: +4522771617; Email: kamilla.woznica.miskowiak@regionh.dk

Study Locations

• Denmark
  • Capital Region Of Copenhagen
    • Frederiksberg, Capital Region Of Copenhagen, Denmark, 2000
      • Recruiting
      • Neurocognition and Emotion in Affective Disorders (NEAD) Centre, Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Frederiksberg hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Fluent Danish skills
• Meet the International Classification of Diseases 10th edition (ICD-10) diagnosis of unipolar disorder, bipolar disorder (types I and II) or a psychosis spectrum disorder (i.e. F20-F29) confirmed using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview
• Patients must have objective and subjective cognitive impairment at the time of inclusion. Objective cognitive impairment is defined a total score on the Screen for Cognitive Impairment in Psychiatry - Danish version (SCIP-D) ≥ 0.5 standard deviations (SD) below the expected total score based on age, education, and gender or as a score ≥ 0.5 SD below the expected score on a minimum of two out of the five subtests (verbal learning test - immediate, working memory test, verbal fluency test, verbal learning, test - delayed, and processing speed test). Subjective cognitive impairment is defined as a score ≥ 14 on the Cognitive Complaints in Bipolar Disorder Rating Scale (COBRA).

Exclusion Criteria:

• Current drug or substance abuse
• A daily use of benzodiazepines >22.5 mg oxazepam or >7.5 mg diazepam (cutoffs for doses with limited cognitive side effects)
• Comorbid neurological disorder
• Previous serious head trauma
• Dyslexia
• Pregnancy
• Claustrophobia (fMRI scan)
• Having a pacemaker or other metal implants inside the body (fMRI scan)
• Having had electroconvulsive therapy in the 3 months prior to inclusion

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Virtual reality Based Cognitive Remediation; The cognitive remediation program has a duration of four weeks and involves two weekly 1,5-hour virtual reality-based cognitive training sessions with a therapist accompanied by additional between-session virtual reality training at home and homework assignments consisting of cognitively challenging daily life tasks.	Behavioral: Virtual reality Based Cognitive Remediation; The main component of the intervention is a virtual reality training platform in 360° Oculus Quest 2-software in which participants train their cognitive abilities guided by the therapist. The platform includes four immersive daily-life scenarios in which patients have consistently reported that they often experience cognitive difficulties: (1) a kitchen scenario focusing on planning and cooking a meal, (2) a supermarket scenario focusing on grocery shopping, (3) a restaurant scenario focusing on remembering names and personal information and (4) an office scenario focusing on planning, initiating, and completing work assignments. The virtual reality training is supported by a psychoeducation program that focuses on application of learned cognitive strategies in daily life.
Sham Comparator: Virtual reality control treatment; The control treatment program also has a duration of four weeks and involves one weekly 2-hour session with a therapist.	Behavioral: Virtual reality control training; The virtual reality control training involves completing different virtual reality games that are available through the Oculus Quest games store.The chosen games involve no direct training of cognitive abilities such as planning skills og strategic learning, but merely involves simple reaction time and interaction with an entertaining environment that is meaningful to the participant and gives the impression of training cognitive skills.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cognition Assessement in Virtual Reality (CAVIR) test: cognitive composite score	The primary outcome measure is a broad cognitive composite score spanning all five subtasks on a novel virtual reality test of daily-life cognitive functions, the Cognition Assessement in Virtual Reality (CAVIR) test. The CAVIR test is a self-administered 360º immersive VR test in a kitchen, where the participant's abilities to plan and prepare a meal are assessed. The test has a duration of 15 minutes and involves five subtasks probing verbal memory, executive functions, processing speed, working memory and sustained attention, respectively. The cognitive composite score is calculated by averaging the z-transformed scores on the five CAVIR subtasks. No score range. Higher scores mean a better outcome.	Baseline, treatment completion (primary outcome assessement time point) and 3-months follow-up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rey Auditory Verbal Learning Test (RAVLT): verbal learning and memory domain composite score	A domain composite of 'verbal learning and memory' comprising the following subtests on the Rays Verbal Learning (RAVLT) Test: RAVLT total recall lists I-V, RAVLT immediate recall, RAVLT delayed recall. Score range 0-120. Higher scores mean a better outcome	Baseline, treatment completion and 3-months follow-up
Assessement of Motor and Process skills (AMPS)	A recommended measure of functioning (i.e. Activity of Daily Living) in individuals with psychiatric illness and cognitive impairment conducted by an AMPS-certificated occupational therapist a standardized test apartment. During an AMPS-evaluation, two domains of performance are evaluated: ADL motor skills (16 items) and ADL process skills (20 items). Scoring of the AMPS assessment is conducted using t available software Occupational Therapy Assessment Package (OTAP) reporting software. OTAP is based on a many-faceted Rasch measurement model making it possible to convert ordinal raw scores into overall linear ADL motor and process ability measures adjusted for severity of the task, skill item difficulty, and rater severity (determined based on rater calibration). A clinically relevant difference has been determined as ≥0.3 logit on the ADL motor or process ability scales. Higher scores mean a better outcome.	Baseline, treatment completion and 3-months follow-up

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
One Touch Stocking of Cambridge	A computerised neuropsychological test assessing executive function. Score range 0-15. Higher scores mean a better outcome	Baseline, treatment completion and 3-months follow-up
Spatial Working Memory test	A computerised neuropsychological test assessing spatial working memory. Score range 2-14. Higher scores mean a better outcome.	Baseline, treatment completion and 3-months follow-up
Rapid Visual Information Processing	A computerised neuropsychological test assessing sustained attention. Score range 0-1. Higher scores mean a better outcome.	Baseline, treatment completion and 3-months follow-up
Wechsler Adult Intelligence Scale Third edition (WAIS-III) letter-number sequencing	Neuropsychological test assessing executive function. Score range 0-21. Higher scores mean a better outcome.	Baseline, treatment completion and 3-months follow-up
Repeatable Battery of the Assessment of Neuropsychological Status (RBANS) Digit Span	Neuropsychological test assessing attention. Score range 0-16. Higher scores mean a better outcome.	Baseline, treatment completion and 3-months follow-up
Repeatable Battery of the Assessment of Neuropsychological Status (RBANS) Coding	Neuropsychological test assessing processing speed. Score range 0-89. Higher scores mean a better outcome.	Baseline, treatment completion and 3-months follow-up
Verbal Fluency with the letter "D" and "S"	Neuropsychological test assessing executive function. No score range. Higher scores mean a better outcome.	Baseline, treatment completion and 3-months follow-up
Trail Making Test A	Neuropsychological test assessing attention. Scored as time to complete. A higher time means a worse outcome.	Baseline, treatment completion and 3-months follow-up
Trail Making Test B	Neuropsychological test assessing executive function. Scored as time to complete. A higher time means a worse outcome.	Baseline, treatment completion and 3-months follow-up
Brief University of California, San Diego Performance-Based Skills Assessment-B (UPSA-B)	Objective assessment of level of functioning. Score range 0-100. Higher scores mean a better outcome.	Baseline, treatment completion and 3-months follow-up
Wisconsin Card Sorting Task	Computerized neuropsychological test assessing executive function. No score range. Higher scores mean a worse outcome.	Baseline, treatment completion and 3-months follow-up
Functional Assessment Short Test	Observer-based rating of level of functioning. Score range 0-72. Higher scores mean a worse outcome.	Baseline, treatment completion and 3-months follow-up
Cognitive Complaints in Bipolar Disorder Rating Assessement (COBRA)	Questionnaire on subjective cognitive complaints. Score range 0-48. Higher scores mean a worse outcome.	Baseline, treatment completion and 3-months follow-up
World Health Organization Quality of Life (WHOQOL-BREF)	Questionnaire on quality of life. Score range 26-130. Higher scores mean a better outcome.	Baseline, treatment completion and 3-months follow-up
Cognitive Difficulties in Everyday Life (CODEL)	Questionnaire on subjective cognitive complaints. Score range 0-48. Higher scores mean a worse outcome	Baseline, treatment completion and 3-months follow-up
Perceived Competence Scale (PCS)	Questionnaire on self-efficacy. Score range 0-49. Higher scores mean a better outcome	Baseline, treatment completion and 3-months follow-up

Collaborators and Investigators

• Sponsor: Mental Health Services in the Capital Region, Denmark
• Collaborators: Rigshospitalet, Denmark; University of Copenhagen; TrygFonden, Denmark
• Investigators: Principal Investigator: Kamilla Woznica Miskowiak, DMSc, DPhil, Mental Health Services in the Capital Region, Denmark

Publications and helpful links

General Publications

• Miskowiak KW, Jespersen AE, Kessing LV, Aggestrup AS, Glenthoj LB, Nordentoft M, Ott CV, Lumbye A. Cognition Assessment in Virtual Reality: Validity and feasibility of a novel virtual reality test for real-life cognitive functions in mood disorders and psychosis spectrum disorders. J Psychiatr Res. 2021 Dec 12;145:182-189. doi: 10.1016/j.jpsychires.2021.12.002. Online ahead of print.

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2022
• Primary Completion (Estimated): June 1, 2025
• Study Completion (Estimated): June 1, 2025

Study Registration Dates

• First Submitted: September 8, 2023
• First Submitted That Met QC Criteria: September 8, 2023
• First Posted (Actual): September 15, 2023

Study Record Updates

• Last Update Posted (Actual): January 9, 2024
• Last Update Submitted That Met QC Criteria: January 6, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: Depression; Schizophrenia; Bipolar Disorder; Cognitive Remediation; Cognitive Impairment; Virtual Reality; Cognition; Psychotic Disorders; Schizotypal Disorder
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mood Disorders; Neurocognitive Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Cognition Disorders; Bipolar and Related Disorders; Depression; Schizophrenia; Psychotic Disorders; Mental Disorders; Cognitive Dysfunction; Bipolar Disorder
• Other Study ID Numbers: H-22004153; P-2022-411 (Other Identifier: Registry ID: Danish Data Protection Agency)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No